Cargando…
Lenacapavir: First Approval
Lenacapavir (Sunlenca(®)) is a long-acting capsid inhibitor of human immunodeficiency virus type 1 (HIV-1) being developed by Gilead Sciences Inc. It is available as an oral tablet and injectable solution, with the latter being a slow-release formulation to allow bi-annual subcutaneous administratio...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10267266/ https://www.ncbi.nlm.nih.gov/pubmed/36272024 http://dx.doi.org/10.1007/s40265-022-01786-0 |